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Abstract
Sepsis and septic shock continue to contribute to our workload
and stimulate our research activities although many fundamental
questions remain. Studies reported on here focus on inotrope use
and a novel way of predicting inotrope response. Continuing this
theme more fundamental work is reported examining the
mitochondrial respiratory chain and the effects of sepsis coupled
with interesting work on lactic acidosis. Troponin raises its head
again and we are still left quizzing over its value in the ICU. Finally
we discuss a paper on the outcome of the obese patient on a
general ICU. Like sepsis a continuing challenge.
Medicine is the only profession that labours incessantly to
destroy the reason for its own existence.
James Bryce (1914)
Choosing the inotrope
Sepsis and septic shock in the intensive care unit (ICU) still
contribute significantly to our workload and, unfortunately,
account for significant mortality. Consequently, they continue
to provide much interest in the literature as our understanding
of the processes involved become ever more complex. An
interesting physiological short term study performed by
Albanese and colleagues [1] addresses a far more basic
aspect to the treatment of septic shock: that is, the choice of
inotrope. In 20 patients, the vasopressors terlipressin and
norepinephrine were compared. The aim of this study was to
compare the two inotropes given the known undesirable
effects of norepinephrine and the observed diminished
vasoreactivity to catecholamines in sepsis [2]. Patients were
recruited if they had a mean arterial pressure (MAP)
<60 mmHg, two or more organ dysfunctions and fulfilled
criteria for septic shock. Norepinephrine was given at a
predetermined incremental rate whereas those randomised to
terlipressin were given a bolus (1 mg). The main findings (well
presented in the discussion) were that both agents effectively
increased MAP and improved renal function. Terlipressin
resulted in a decrease in heart rate and cardiac index but no
change in stroke volume index. Oxygen delivery and
consumption index were also decreased with terlipressin.
This observation was probably a reflection of decreased
chronotropic drive with terlipressin. Is this important? Given
the small sample size, no firm conclusions can be made,
although the lack of detrimental effect on oxygen delivery
suggests not. One wonders if the use of terlipressin may soon
become commonplace in this interesting but difficult group of
patients. On the same theme, Levy and colleagues from France
report an interesting and rather brave study in septic shock [3].
In this prospective study, 110 patients with septic shock as a
presumptive initial diagnosis were treated, following adequate
volume resuscitation, with an incremental dopamine
‘challenge’. An initial dose of 10 µg/kg/minute was employed
for 10 minutes and increased to 15 µg/kg/minute after
10 minutes followed by a further increase to 20 µg/kg/minute;
the aim was a MAP of 70 mmHg. ‘Dopamine responders’ were
defined by an increase of >15% of cardiac output after
vascular loading. Those deemed resistant were treated with
alternative agents. Overall mortality was approximately 54%
(similar to that in the report by Albanese et al.). Risk of death
was associated with the usual suspects, including simplified
acute physiology score (SAPS II), sepsis-related organ failure
assessment (SOFA), MAP <60 mmHg, increased lactate and,
surprisingly, the use of hydrocortisone, although as the
authors point out this study was performed before low-dose
steroid recommendations were applied. They did observe,
however, a rather dramatic difference in the groups. Those
deemed ‘responders’ had an overall mortality of 16%
whereas those deemed ‘non-responders’ had a mortality of
78%. Granted, the study is open to some minor criticisms
(mainly some differences in the baseline characteristics of the
two groups as well as non-standardisation of volume
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resuscitation) but it does open some interesting doors. It
would seem intuitive that patients who respond to treatment
quickly may have better outcomes and it is well established
that catecholamine resistance is associated with a bleak
prognosis [4]. This study, however, provides a rapid means by
which the overall outlook of a patient can be assessed quickly.
What we do with these data is somewhat more difficult. The
mortality in the non-responders was 78% and not 100%. They
may, therefore, identify individuals who could benefit from
aggressive escalation of other aspects of our armoury. They
may also provide us with useful information with which to
discuss possible outcomes with relatives. We await the first
paper on terlipressin responsiveness with interest!
Sepsis and mitochondria
From treatment of sepsis we turn to more fundamental
questions. Much attention has focused recently on
microcirculatory and mitochondrial dysfunction in sepsis [5]
and a study reported in the American Journal of Respiratory
Critical Care Medicine expands our knowledge further [6].
Employing an endotoxin mediated rodent model of sepsis, the
authors examined changes in mitochondrial protein expres-
sion and mitochondrial function. Mitochondria were isolated
from the diaphragm following endotoxin administration, which
resulted in a marked reduction (approximately 50%) in
mitochondrial oxygen consumption. Moreover, reductions in
NADH oxidase activity and uncoupled respiration were seen.
Uniquely, the authors also demonstrated a significant
depletion in the protein subunits of complex I, III, IV and V,
most of which are iron-sulphur cluster containing. The
implication is, therefore, that specific proteins integrally
involved in electron transport are selectively depleted,
resulting, presumably, in impaired mitochondrial function and
hence ATP production. As the authors point out, an important
goal for further studies will be to try and elucidate the exact
biochemical processes responsible for this observation. We
may achieve the sepsis magic bullet after all. Associated with
a potential derangement in mitochondrial function is the
process, well known among intensivists, of lactic acidosis.
Revelly and colleagues [7] provide us with some new insights
into this process. Patients with either septic shock or
cardiogenic shock were infused with 13C-labelled sodium
lactate; lactate clearance and metabolism were compared to
those in normal individuals. The conclusions, in keeping with
other work, suggest that lactate clearance is similar in all
groups and that hyperlactaemia relates to increased
production [8]. The observed hyperlactaemia seemed to be
related to increased glucose turnover. This provides further
evidence for the theory that lactic acid per se is not
responsible for the acidosis but is a marker of enhanced
glycolysis. The initial step of proton production, namely
hydrolysis of fructose 1,6 diphosphate, occurs but the
‘normal’ process of proton elimination through conversion to
the weak acid with the volatile anhydride (i.e. carbonic acid)
does not. This results in the ensuing acidosis. No doubt this
debate will continue to run and run.
Yet more on troponin
We all recognise the poor cardiac performance seen in
sepsis and the introduction of the measurement of serum
troponin I seemed to offer us a definitive answer to this
conundrum. Since those heady days of nearly 20 years ago
thousands of papers have been published on the use, abuse
and misuse of this test. The problem with any investigation is
the interpretation and nowhere is this more so than in the
ICU where elevated troponin concentrations have been
observed in up to a third of admissions [9]. Increasingly,
elevations in troponin are recognised as a prognostic
indicator in the absence of myocardial infarction and the
study by Quenot et al. [10] addresses the role of troponin as
an independent prognostic indicator in the ICU rather than a
diagnostic test. They examined all medical admissions over a
six month period excluding all with electrocardiographic
changes or symptoms of an acute myocardial infarction
(AMI), those who had received cardiac massage and
patients with significant systolic dysfunction (ejection
fraction <50% on echocardiography). Of the 217 patients
included, 69 (32%) had raised troponin I levels. This group
were older, had higher SAPS II scores and had a higher
incidence of mechanical ventilation. Multivariate analysis
seemed to support the view that raised troponin was indeed
a marker of poor outcome as defined by in-hospital mortality.
How this relates to practice is difficult to assess. Lim et al.
[11] adopted a thoughtful approach to the troponin/
infarction debate. They performed a prospective cohort
study on all patients admitted to a single unit over a two
month period. Where AMI was suspected, all
electrocardiographs (ECGs), troponin levels and echo-
cardiographic results for these patients were collected.
Evidence of myocardial infarction was based on standard
guidelines plus either a rise or fall in troponin T and any
regional wall abnormality demonstrated on echo-
cardiography. Of 115 pateints selected, 81% had both
ECGs and troponin levels determined at least once: 24 of
these were deemed to have had an AMI as defined by their
own criteria. These patients had, unsurprisingly, a poorer
outcome. In a very honest discussion, the authors
acknowledge the limitations of their study while highlighting
the important questions that warrant further thought. Firstly,
that diagnosis of AMI with the current guidelines is difficult in
a critical care setting as they are designed for a non-ICU
population. Their unilateral amendments to the diagnostic
criteria certainly need to be refined to be of use, but are a
welcome step in the right direction. Secondly, diagnosing an
AMI is essential as conventional treatments may provide
huge morbidity and mortality benefits, whereas the same
treatments in patients with non-ischaemic rises in troponin
may be disastrous. Finally, they argue strongly for clinicians
to think before requesting a troponin test and to ensure that
the other criteria for AMI are at least being looked for. A
troponin test has no chance of being interpretable if it has no
accompanying ECG. The questions that need to be
answered as regards positive troponin tests in the ICU537
setting have been succinctly summarised [12]. It is important
to differentiate between thrombotic acute coronary
syndromes and other causes of troponin elevation wherever
possible, as the management and prognosis may be so
different for the two subsets. Once again, the question of
what to do even if it is a true acute coronary syndrome is not
yet known – conventional treatments for AMI have yet to be
fully evaluated in the context of the critically ill patient. For
the moment, we should be giving ourselves a chance to
make the diagnosis by correlating the troponin test with
other tests – certainly the ECG – in all patients.
Treating the obese in ICU
A subject rarely out of the popular press these days is that
of the obesity epidemic and it is somewhat staggering that
in 1998, 55% of the adult North American population were
deemed as being overweight or obese [13]. Increasingly,
this patient population finds its way to the ICU and
practicing clinicians are often concerned with regard to the
special problems these patients present. The underlying
ventilation-perfusion mismatch causing hypoxia is well
known as are the difficulties associated with mechanical
ventilation, weaning and the risk of ventilator associated
pneumonia [14,15]. Given this knowledge, perhaps there is
a general feeling that the obese, and particularly the
morbidly obese, fare badly in the intensive care setting. The
prospective study by Ray et al. [16] examined 2,148
patients admitted to a 9 bed general ICU/high dependency
unit and classified patients into groups based on the
calculated body mass index. This study provides some
interesting insights into this issue. This cohort accounted
for 76% of admissions over the study period of 44 months.
Groups were compared by age, APACHE II score, mortality,
ICU length of stay, need for ventilation and length of
ventilation. The significant finding was that the morbidly
obese (body mass index >40) were more frequently female
and younger. Adverse events included evidence of infection,
problems with intubation, haemorrhage, prolonged
paralysis, deep vein thrombosis or pneumothorax and
showed no statistical significance. These were expressed
on a per-patient basis as opposed to a per-procedure basis,
which may obscure a true difference in rates. Also of note is
that only 50% of the patients required mechanical
ventilation, the area of most concern in obese patients. An
interesting observation was that the severely obese were
female and younger, although the age difference was only
present in those surviving to hospital discharge, confirming
one prejudice at least. The overall findings are interesting in
that this study did not demonstrate any significant problems
in the obese over and above those for the rest of the
population. We were slightly confused, however, with the
conclusion that “studies using larger populations were
needed to confirm these observations”!
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